Garry Nolan Ph.D. is Director at Akoya Biosciences, Inc. (AKYA). They have made 9 open-market trades across 1 company since 2021, most recently 2022-12-13.
CIK 0001857405
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKYA | 555,084 | $716K |
Shares reported on the most recent Form 4, priced at the 2023-03-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKYA | SELL | 2022-12-13 | 2023-03-27 | $13.25 | $1K | -12.0% | -17.0% | -16.4% |
| AKYA | SELL | 2022-12-02 | 2022-12-06 | $13.25 | $15K | -0.6% | -26.2% | -9.3% |
| AKYA | SELL | 2022-12-01 | 2022-12-02 | $13.36 | $67K | -3.1% | -27.2% | -11.9% |
| AKYA | SELL | 2022-11-16 | 2022-11-17 | $13.25 | $4K | -1.4% | -11.2% | -5.6% |
| AKYA | SELL | 2022-11-10 | 2022-11-14 | $13.30 | $375K | -3.2% | -6.6% | -8.7% |
| AKYA | SELL | 2022-09-14 | 2022-09-16 | $13.26 | $220K | -4.0% | +6.6% | +3.6% |
| AKYA | SELL | 2022-09-09 | 2022-09-13 | $13.31 | $615K | -11.9% | -3.5% | +2.7% |
| AKYA | SELL | 2021-12-13 | 2022-12-15 | $13.25 | $1K | -27.9% | -10.7% | -28.6% |
| AKYA | SELL | 2021-12-09 | 2021-12-13 | $12.67 | $317K | +13.0% | +4.5% | -12.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.